Anna Rebizak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Rebizak has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aneta Rasińska
Municipal Hospital No. 4 in Gliwice Ltd. Zygmunta Starego 20, 44-100, Poland
4 shared publications - Aneta Rostkowska
Independent Public Clinical Hospital named after Prof. W. Orłowski, ul. Czerniakowska 231, 00-416 Warszawa, Poland
4 shared publications - Anna Rzyczniok
Ślaski Uniwersytet Medyczny
4 shared publications - Justyna Jachimczak
Our Lady of Perpetual Help Hospital in Wołomin, 05-200 Wołomin, ul. Gdyńska 1/3, Poland
4 shared publications - Justyna Matusik
Academy of Silesia in Katowice, 40-555 Katowice, ul. Rolna 43, Poland
4 shared publications - Natalia Pasierb
Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland
4 shared publications
Latest Publications
- Open Access
- 12 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 61400
High-Frequency Ultrasonography As An Innovative Diagnostic Method in Dermatology
Ultrasonography is now a standard, non-invasive imaging technique used in many areas of medical diagnostics. Currently it is also an important tool in the diagnosis of skin diseases. In clinical practice, High Frequency Ultrasonography (HFU) is used more and more often because it has proved to be a valuable diagnostic tool for assessing the condition of skin tissue. The physical conditions of HFU make it possible to estimate the parameters of the skin structure, such as thickness and echogenicity (a feature related to the center) of its layers in relation to the surrounding tissues. Therefore, HFU allows to obtain information concerning the condition of the examined area of the skin., the rate of lession development and the effectiveness of implemented theraphy. HFU is applied in the imaging of focal skin lesions, including melanoma, basal-cell carcinoma, inflammatory skin diseases, diseases associated with its thickening and in aesthetic medicine and cosmetology. The aim of this chapter is to familiarize the reader interested in dermatology and in particular diagnostics in this field, the possibilities associated with the use of HFU. Material and Methods – Narrative literature review combined with technical exposition of HFU devices (20–100 MHz mechanical and broadband linear probes). The authors summarise depth–resolution trade-offs, standard scanning protocols and representative clinical images to illustrate HFU performance across anatomical sites and skin conditions. Findings – HFU resolves skin strata down to 10 μm, quantifies tumour thickness (Breslow depth) pre-operatively, delineates BCC margins, detects subepidermal low-echogenic band as a marker of photoageing or atopic dermatitis severity, and guides real-time assessment of fillers, vascular flow, oedema and fibrosis. Frequencies of 20–30 MHz visualise full dermis, 50 MHz epidermis/upper dermis, while lower (7–12 MHz) probes image deeper lesions and lymph nodes.
- 12 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 61400
Open AccessHigh-Frequency Ultrasonography As An Innovative Diagnostic Method in Dermatology
Ultrasonography is now a standard, non-invasive imaging technique used in many areas of medical diagnostics. Currently it is also an important tool in the diagnosis of skin diseases. In clinical practice, High Frequency Ultrasonography (HFU) is used more and more often because it has proved to be a valuable diagnostic tool for assessing the condition of skin tissue. The physical conditions of HFU make it possible to estimate the parameters of the skin structure, such as thickness and echogenicity (a feature related to the center) of its layers in relation to the surrounding tissues. Therefore, HFU allows to obtain information concerning the condition of the examined area of the skin., the rate of lession development and the effectiveness of implemented theraphy. HFU is applied in the imaging of focal skin lesions, including melanoma, basal-cell carcinoma, inflammatory skin diseases, diseases associated with its thickening and in aesthetic medicine and cosmetology. The aim of this chapter is to familiarize the reader interested in dermatology and in particular diagnostics in this field, the possibilities associated with the use of HFU. Material and Methods – Narrative literature review combined with technical exposition of HFU devices (20–100 MHz mechanical and broadband linear probes). The authors summarise depth–resolution trade-offs, standard scanning protocols and representative clinical images to illustrate HFU performance across anatomical sites and skin conditions. Findings – HFU resolves skin strata down to 10 μm, quantifies tumour thickness (Breslow depth) pre-operatively, delineates BCC margins, detects subepidermal low-echogenic band as a marker of photoageing or atopic dermatitis severity, and guides real-time assessment of fillers, vascular flow, oedema and fibrosis. Frequencies of 20–30 MHz visualise full dermis, 50 MHz epidermis/upper dermis, while lower (7–12 MHz) probes image deeper lesions and lymph nodes.
- Open Access
- 12 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 61402
The Role of Microbial Factors in the Pathogenesis of Male Infertility: A Literature Review
The influence of infectious diseases on the development of infertility continues to be an area of active research. This review explores how the microbial environment within the male reproductive system may contribute to infertility. It examines how certain pathogenic characteristics of microorganisms can lead to reproductive issues when inflammation occurs in the male urogenital tract, focusing on how such infections impact sperm quality - such as reducing sperm count, impairing motility, altering morphology, and diminishing fertilization potential. Additionally, the review addresses how the body’s immune response and its resistance mechanisms may play a role in sustaining chronic inflammation in male reproductive organs. Purpose: To delineate how specific microbial communities and pathogen-linked virulence traits contribute to male infertility by disrupting spermatogenesis, sperm function and local immune homeostasis in the urogenital tract. Material and Methods: Narrative literature review based on a systematic search of microbiology, andrology and urology studies that compared semen microbiota, immune markers and clinical outcomes between proven-fertile and infertile men; key in-vitro and animal mechanistic papers were also appraised to integrate pathophysiological insights. Findings: Infertile semen shows a reproducible shift from protective Gram-positive Lactobacillus/Corynebacterium spp. to opportunistic Escherichia coli, Gardnerella, anaerobic Bacteroides and coagulase-negative staphylococci. Uropathogenic E. coli fimbriae, toxins and stress proteins, high anti-lysozyme staphylococci and Chlamydia/Ureaplasma lipopolysaccharides induce sperm agglutination, oxidative DNA damage and apoptosis. Declines in seminal lysozyme, lactoferrin and zinc - particularly in chronic prostatitis or hyper-viscous semen - halve bactericidal capacity, allowing chronic inflammation to persist.
- 12 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 61402
Open AccessThe Role of Microbial Factors in the Pathogenesis of Male Infertility: A Literature Review
The influence of infectious diseases on the development of infertility continues to be an area of active research. This review explores how the microbial environment within the male reproductive system may contribute to infertility. It examines how certain pathogenic characteristics of microorganisms can lead to reproductive issues when inflammation occurs in the male urogenital tract, focusing on how such infections impact sperm quality - such as reducing sperm count, impairing motility, altering morphology, and diminishing fertilization potential. Additionally, the review addresses how the body’s immune response and its resistance mechanisms may play a role in sustaining chronic inflammation in male reproductive organs. Purpose: To delineate how specific microbial communities and pathogen-linked virulence traits contribute to male infertility by disrupting spermatogenesis, sperm function and local immune homeostasis in the urogenital tract. Material and Methods: Narrative literature review based on a systematic search of microbiology, andrology and urology studies that compared semen microbiota, immune markers and clinical outcomes between proven-fertile and infertile men; key in-vitro and animal mechanistic papers were also appraised to integrate pathophysiological insights. Findings: Infertile semen shows a reproducible shift from protective Gram-positive Lactobacillus/Corynebacterium spp. to opportunistic Escherichia coli, Gardnerella, anaerobic Bacteroides and coagulase-negative staphylococci. Uropathogenic E. coli fimbriae, toxins and stress proteins, high anti-lysozyme staphylococci and Chlamydia/Ureaplasma lipopolysaccharides induce sperm agglutination, oxidative DNA damage and apoptosis. Declines in seminal lysozyme, lactoferrin and zinc - particularly in chronic prostatitis or hyper-viscous semen - halve bactericidal capacity, allowing chronic inflammation to persist.
- Open Access
- 4 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 41, 59955
Application of a PCSK9 inhibitor in the treatment of lipid disorders – a comprehensive literature
Lipid disorders stem from imbalances in the levels of cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides (TG). Among Polish adults over the age of 18, these conditions may affect as many as 60–80% of individuals. Such high prevalence is closely linked to the occurrence of cardiovascular diseases, for which dyslipidemias serve as a key contributing factor. Unfortunately, these disorders are also the leading cause of premature death in Poland. Consequently, the appropriate management of blood lipid concentrations—through both well-selected pharmacotherapy and supportive non-pharmacological measures—plays a vital role in reducing related risks. The primary class of lipid-lowering drugs comprises 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins. Their principal mechanism involves lowering LDL-C to levels commensurate with the patient’s cardiovascular risk profile. Should these targets remain unmet, additional agents can be employed, such as ezetimibe in conjunction with statins, or a newer group of lipid-lowering medications known as PCSK9 inhibitors, used either as monotherapy or in combination. These drugs are monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). Purpose: This paper briefly examines the role of PCSK9 inhibitors in managing dyslipidemia and their impact on reducing LDL cholesterol and preventing cardiovascular events. Material and Methods: We reviewed available literature, clinical trials, and guidelines on PCSK9 biology and the effectiveness and safety of PCSK9 inhibitors compared to other lipid-lowering therapies. Findings: PCSK9 inhibitors (alirocumab, evolocumab) can lower LDL-C by up to 60%. They can be used alone or with statins/ezetimibe, offer a favorable safety profile, and significantly reduce cardiovascular risk.
- 4 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 41, 59955
Open AccessApplication of a PCSK9 inhibitor in the treatment of lipid disorders – a comprehensive literature
Lipid disorders stem from imbalances in the levels of cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides (TG). Among Polish adults over the age of 18, these conditions may affect as many as 60–80% of individuals. Such high prevalence is closely linked to the occurrence of cardiovascular diseases, for which dyslipidemias serve as a key contributing factor. Unfortunately, these disorders are also the leading cause of premature death in Poland. Consequently, the appropriate management of blood lipid concentrations—through both well-selected pharmacotherapy and supportive non-pharmacological measures—plays a vital role in reducing related risks. The primary class of lipid-lowering drugs comprises 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins. Their principal mechanism involves lowering LDL-C to levels commensurate with the patient’s cardiovascular risk profile. Should these targets remain unmet, additional agents can be employed, such as ezetimibe in conjunction with statins, or a newer group of lipid-lowering medications known as PCSK9 inhibitors, used either as monotherapy or in combination. These drugs are monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). Purpose: This paper briefly examines the role of PCSK9 inhibitors in managing dyslipidemia and their impact on reducing LDL cholesterol and preventing cardiovascular events. Material and Methods: We reviewed available literature, clinical trials, and guidelines on PCSK9 biology and the effectiveness and safety of PCSK9 inhibitors compared to other lipid-lowering therapies. Findings: PCSK9 inhibitors (alirocumab, evolocumab) can lower LDL-C by up to 60%. They can be used alone or with statins/ezetimibe, offer a favorable safety profile, and significantly reduce cardiovascular risk.
- Open Access
- 4 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 41, 59940
Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
Lung cancer has, for several decades, been the second most frequently diagnosed malignancy and the leading cause of cancer death worldwide. It continues to pose a significant burden on healthcare systems and a serious challenge for clinicians and patients. The majority of patients present with advanced disease at diagnosis, and most survive less than five years. Although novel targeted therapies have been introduced in recent years, there remains a significant demand for treatments capable of improving response and prolonging survival while having minimal impact on quality of life. Recent clinical evidence supporting immunotherapeutic approaches indicates that they may represent the next major therapeutic breakthrough in lung cancer management. Non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancers, was once considered a non-immunogenic disease; yet, as with several other malignancies, emerging data suggest that in most cases, the lack of immune response is functional and can be therapeutically overcome. Purpose: To provide a comprehensive review of immunotherapy as an innovative therapeutic approach for non-small cell lung cancer (NSCLC), highlighting the role of key immune mechanisms and checkpoint inhibitors. Material and Methods: The authors conducted a detailed literature review examining the immune context of NSCLC, discussing the significance of PD-1/PD-L1 and CTLA-4 checkpoints, relevant clinical trials, and emerging biomarkers like PD-L1 expression and tumor mutational burden. Findings: Immunotherapy, particularly PD-1/PD-L1 inhibitors, substantially improves survival in advanced NSCLC and can be enhanced by combination strategies. Biomarkers help identify patients most likely to benefit while guiding treatment choices.
- 4 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 41, 59940
Open AccessImmunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
Lung cancer has, for several decades, been the second most frequently diagnosed malignancy and the leading cause of cancer death worldwide. It continues to pose a significant burden on healthcare systems and a serious challenge for clinicians and patients. The majority of patients present with advanced disease at diagnosis, and most survive less than five years. Although novel targeted therapies have been introduced in recent years, there remains a significant demand for treatments capable of improving response and prolonging survival while having minimal impact on quality of life. Recent clinical evidence supporting immunotherapeutic approaches indicates that they may represent the next major therapeutic breakthrough in lung cancer management. Non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancers, was once considered a non-immunogenic disease; yet, as with several other malignancies, emerging data suggest that in most cases, the lack of immune response is functional and can be therapeutically overcome. Purpose: To provide a comprehensive review of immunotherapy as an innovative therapeutic approach for non-small cell lung cancer (NSCLC), highlighting the role of key immune mechanisms and checkpoint inhibitors. Material and Methods: The authors conducted a detailed literature review examining the immune context of NSCLC, discussing the significance of PD-1/PD-L1 and CTLA-4 checkpoints, relevant clinical trials, and emerging biomarkers like PD-L1 expression and tumor mutational burden. Findings: Immunotherapy, particularly PD-1/PD-L1 inhibitors, substantially improves survival in advanced NSCLC and can be enhanced by combination strategies. Biomarkers help identify patients most likely to benefit while guiding treatment choices.